Precigen (PGEN) Free Cash Flow (2012 - 2026)
Precigen (PGEN) posted quarterly Free Cash Flow of -$44.0 million for Q1 2026, down 159.78% year-over-year from $73.6 million in Q1 2025, and down 87.52% quarter-over-quarter from -$23.5 million in Q4 2025.
Analysis
Precigen (PGEN) Free Cash Flow (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Free Cash Flow for 15 consecutive years, with -$44.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 159.78% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$116.9 million (down 74.43% YoY), while the FY2025 annual figure was -$89.8 million, down 31.11% from the prior year.
- Free Cash Flow declined to -$44.0 million in Q1 2026 per PGEN's latest filing, from -$23.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.0 million in Q4 2024 and bottomed at -$44.0 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$20.0 million across 5 years, with a median of -$18.4 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow soared 93.51% — and 2025, when it plunged 2183.85%.
- Precigen's Free Cash Flow stood at -$15.4 million in 2022, then dropped by 2.54% to -$15.8 million in 2023, then jumped by 93.51% to -$1.0 million in 2024, then slumped by 2183.85% to -$23.5 million in 2025, then tumbled by 87.52% to -$44.0 million in 2026.
- Business Quant data shows PGEN's Free Cash Flow at -$44.0 million in Q1 2026, -$23.5 million in Q4 2025, and -$30.8 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | -18.20 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18.20 Mn |
| Mar 31, 2026 | -44.09 Mn |
| Dec 31, 2025 | -23.48 Mn |
| Sep 30, 2025 | -29.46 Mn |
| Jun 30, 2025 | -19.70 Mn |
| Mar 31, 2025 | -17.19 Mn |
| Dec 31, 2024 | -9.27 Mn |
| Sep 30, 2024 | -23.62 Mn |
| Jun 30, 2024 | -25.43 Mn |
| Mar 31, 2024 | -18.44 Mn |
| Dec 31, 2023 | -16.53 Mn |
| Sep 30, 2023 | -17.53 Mn |
| Jun 30, 2023 | -15.87 Mn |
| Mar 31, 2023 | -18.54 Mn |
| Dec 31, 2022 | -15.45 Mn |
| Sep 30, 2022 | -25.39 Mn |
| Jun 30, 2022 | -8.77 Mn |
| Mar 31, 2022 | -20.36 Mn |
| Dec 31, 2021 | -17.36 Mn |
| Sep 30, 2021 | -19.29 Mn |